Harbour BioMed Taps Bristol Myers Squibb Veteran to Lead Immunology Innovation
Event summary
- Harbour BioMed appoints Dr. Jenny Xie as Chief Scientific Officer, Immunology and Head of Global External Innovation, effective March 19, 2026.
- Dr. Xie brings 25+ years of biopharmaceutical experience, including leadership roles at Bristol Myers Squibb and Merck.
- She will oversee global external innovation strategy in immunology and manage the Harbour BioMed-AstraZeneca Innovation Lab in Beijing.
- Dr. Xie reports directly to Harbour BioMed CEO Dr. Jingsong Wang.
The big picture
Harbour BioMed's appointment of Dr. Jenny Xie underscores its push to strengthen immunology capabilities through experienced leadership. The move comes as biopharma companies increasingly rely on strategic partnerships and external innovation to bolster pipelines. With Dr. Xie's background in autoimmune disease research and cross-functional leadership, the company aims to enhance its competitive position in the crowded antibody therapeutics space.
What we're watching
- Pipeline Acceleration
- How Dr. Xie's leadership will impact Harbour BioMed's immunology pipeline development and partnership strategy.
- Collaboration Dynamics
- Whether the AstraZeneca Innovation Lab collaboration will yield near-term clinical advancements.
- Talent Retention
- The pace at which Harbour BioMed can attract and retain top biopharma talent to sustain its growth.